Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer 19/09/2025
The U.S. FDA accelerated the approval of Tarlatamab-dlle for the treatment of broad-stage small cell lung cancer 05/09/2025
The U.S. FDA approved Ensartinib for ALK-positive locally advanced or metastatic NSCLC approval focus 04/07/2025
The efficacy of the KRAS G12C inhibitor adagrasib in the second-line treatment of non-small cell lung cancer has been confirmed KRYSTAL-12 05/06/2025
The new KRAS G12C target drug glecirasib shows therapeutic potential. Data from the phase II clinical trial actively target the objective remission rate of treated KRAS G12C mutant non-small cell lung cancer reached 47.9.% 05/06/2025
A new breakthrough in the treatment of KRAS mutant non-small cell lung cancer: combination therapy is expected to overcome drug resistance. Research reveals the potential of sotorasib in combination with the experimental drug FGTI-2734. 05/06/2025
Adagrasib in combination with Cetuximab: A potential new option for colorectal cancer with KRAS G12C mutation 04/06/2025
Adagrasib combined with Cetuximab for the treatment of KRAS G12C mutant colorectal cancer: the KRYSTAL-1 trial shows breakthrough results 04/06/2025
Repotrectinib, a new lung cancer drug in the United States, was approved, and 79% of patients' tumors shrank significantly! 29/11/2023
